Vegalab, a Swiss biotechnology company, has entered into a North American distribution agreement with PL Story, the owner of the YOULIEF dermocosmetic brand. At the same time, the brand also established a separate research collaboration with Plcoskin, a Korean regenerative medicine developer, to combine Vegalab's nano-encapsulation technology with Plcoskin's biopolymer science for potential applications in tissue regeneration and post-procedure skincare.
Under the distribution arrangement, Vegalab is now responsible for bringing the YOULIEF range — which includes the CICA line, DIA serums, ECW ampoule — and sun care products, to consumers in the United States and Canada.
The research collaboration, which pairs Vegalab's multi-layer biopolymer capsules engineered to release active ingredients upon specific triggers with Plcoskin's biodegradable polymer scaffolds and collagen structures used in regenerative medicine, represents a convergence of complementary expertise, as both companies essentially work with polymers that must perform predictably over time, albeit at different scales and in different biological contexts
Strategic Biotechnology Skincare Partnerships
Vegalab Partners with PL Story and Plcoskin
Trend Themes
-
Biotech-enhanced Dermocosmetics — Advanced encapsulation systems and regenerative polymers are reshaping skincare into a more science-led category with higher-performance post-procedure and therapeutic positioning.
-
Cross-border Beauty Partnerships — International distribution and research alliances are creating faster pathways for niche biotechnology skincare brands to enter North American premium beauty markets.
-
Trigger-release Active Delivery — Stimuli-responsive capsules introduce more precise ingredient delivery models that could differentiate clinical skincare through timed, targeted, and condition-specific performance.
Industry Implications
-
Skincare — Dermocosmetic brands are gaining new value through biotechnology platforms that bridge everyday beauty routines with clinical recovery and skin barrier support.
-
Biotechnology — Nano-encapsulation and biopolymer expertise are expanding beyond pharmaceutical contexts into consumer-facing categories where efficacy claims and formulation sophistication matter.
-
Regenerative Medicine — Collagen structures and biodegradable scaffolds have adjacent commercial potential in post-treatment skincare formats that support healing, repair, and tissue-focused care.